P706 Lower need for adalimumab dose intensification in IBD patients treated with combined immune suppression compared with adalimumab monotherapy
P706 Lower need for adalimumab dose intensification in IBD patients treated with combined immune suppression compared with adalimumab monotherapy is a paper indexed in ScholarIQ from OpenAlex.
How many citations does P706 Lower need for adalimumab dose intensification in IBD patients treated with combined immune suppression compared with adalimumab monotherapy have?
P706 Lower need for adalimumab dose intensification in IBD patients treated with combined immune suppression compared with adalimumab monotherapy has 2 citations in the OpenAlex counts ScholarIQ stores.
When was P706 Lower need for adalimumab dose intensification in IBD patients treated with combined immune suppression compared with adalimumab monotherapy published?
P706 Lower need for adalimumab dose intensification in IBD patients treated with combined immune suppression compared with adalimumab monotherapy has 2018 year in the ScholarIQ index.
What is the open-access status of P706 Lower need for adalimumab dose intensification in IBD patients treated with combined immune suppression compared with adalimumab monotherapy?
P706 Lower need for adalimumab dose intensification in IBD patients treated with combined immune suppression compared with adalimumab monotherapy has bronze oa status in the ScholarIQ index.
What is the DOI of P706 Lower need for adalimumab dose intensification in IBD patients treated with combined immune suppression compared with adalimumab monotherapy?
The DOI for P706 Lower need for adalimumab dose intensification in IBD patients treated with combined immune suppression compared with adalimumab monotherapy is on the source record.
What is the OpenAlex record for P706 Lower need for adalimumab dose intensification in IBD patients treated with combined immune suppression compared with adalimumab monotherapy?
The OpenAlex for P706 Lower need for adalimumab dose intensification in IBD patients treated with combined immune suppression compared with adalimumab monotherapy is on the source record.